Evaxion announces business update and first quarter 2025 financial results
Provided By GlobeNewswire
Last update: May 27, 2025
COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results.
Read more at globenewswire.com
